Ptc Therapeutics (PTCT) Research & Development (2012 - 2026)

Ptc Therapeutics' Research & Development history runs 15 years deep, the most recent figure standing at $100.9 million for Q1 2026.

• In Q1 2026, Research & Development fell 7.43% year-over-year to $100.9 million; the TTM figure through Mar 2026 stood at $447.1 million (down 15.2% YoY), while the FY2025 annual figure was $455.2 million, down 14.82% from the prior year.
• Research & Development was $100.9 million for Q1 2026 at Ptc Therapeutics, down from $133.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $195.1 million in Q1 2023 to a low of $100.2 million in Q3 2025.
• Historically, Research & Development has averaged $141.7 million across 5 years, with a median of $133.1 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Research & Development soared 39.3% in 2023, then sank 40.48% in 2024.
• A 5-year view of Research & Development shows it stood at $188.7 million in 2022, then plunged by 35.69% to $121.4 million in 2023, then gained by 2.82% to $124.8 million in 2024, then gained by 6.7% to $133.1 million in 2025, then declined by 24.23% to $100.9 million in 2026.
• The last three Research & Development figures came in at $100.9 million (Q1 2026), $133.1 million (Q4 2025), and $100.2 million (Q3 2025), per Business Quant data.